Compare AbCellera Biologics Inc (ABCL) vs Global X SuperDividend ETF (SDIV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Global X SuperDividend ETF — how do they compare? AbCellera Biologics Inc trades at $7.12 (market cap $2.35B), while Global X SuperDividend ETF trades at $24.24. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, Global X SuperDividend ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | SDIV | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $8.12 | $26.34 |
52-Week Low | $2.78 | $22.90 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
SDIV trades at $24.46, down 0.37% on the day, with a bullish technical signal driven by strong buy indicators despite bearish moving averages. The ETF offers a high dividend yield, recently paying $0.18 per share quarterly, attracting income-focused investors. Recent news highlights its role in diversified portfolios for retirees seeking steady cash flow, with a current yield around 9%.
Outlook is supported by yield appeal in a higher-rate environment, but risks include sensitivity to interest rates and limited tech exposure. Analysts view it as a diversification tool amid AI sector concentration, though valuation metrics are not fully disclosed. Institutional activity shows mixed signals with recent buying and selling.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Global X SuperDividend ETF
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →
